Gufic Biosciences Limited (BOM:509079)
India · Delayed Price · Currency is INR 314.00
0.00 (0.00%)
At close: Feb 12, 2026
Gufic Biosciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 569.19 | 696.5 | 861.36 | 797.05 | 958.4 | 442.32 |
Depreciation & Amortization | 274.23 | 205.34 | 167.57 | 221.03 | 188.88 | 162.72 |
Other Amortization | 5.31 | 5.31 | 2.61 | 1.78 | 0.41 | 0.14 |
Loss (Gain) From Sale of Assets | -0.07 | -1.16 | 23 | -0.3 | -0.68 | 0.37 |
Asset Writedown & Restructuring Costs | - | - | - | - | - | 0.21 |
Stock-Based Compensation | 1.74 | 1.04 | - | - | - | - |
Other Operating Activities | 299.54 | 244.23 | 173.21 | 67.1 | 22.59 | 185.2 |
Change in Accounts Receivable | -372.89 | 73.66 | -1,532 | -553.16 | -231.93 | -189.9 |
Change in Inventory | -428.25 | -163.87 | -170.25 | -678.91 | -211.62 | 280.57 |
Change in Accounts Payable | 573.95 | 164.64 | 400.36 | -120.46 | 336.35 | -9.12 |
Operating Cash Flow | 922.75 | 1,226 | -74.57 | -265.87 | 1,062 | 872.51 |
Operating Cash Flow Growth | 32.48% | - | - | - | 21.76% | 85.24% |
Capital Expenditures | -503 | -755.26 | -1,127 | -1,876 | -874.53 | -123.99 |
Sale of Property, Plant & Equipment | 0.01 | 47.67 | 45.66 | 0.32 | 0.68 | - |
Investment in Securities | - | - | -10 | -7.77 | - | - |
Other Investing Activities | 12.56 | -0.19 | 67.39 | -23.81 | -72.04 | 57.07 |
Investing Cash Flow | -490.44 | -707.77 | -1,024 | -1,907 | -945.89 | -66.93 |
Short-Term Debt Issued | - | 168.04 | 423.44 | 1,426 | - | - |
Long-Term Debt Issued | - | - | - | 1,075 | 119.71 | 117.89 |
Total Debt Issued | 655.3 | 168.04 | 423.44 | 2,501 | 119.71 | 117.89 |
Short-Term Debt Repaid | - | - | - | - | -60.78 | -731.81 |
Long-Term Debt Repaid | - | -321.27 | -457.62 | -66.19 | -61.87 | -34.44 |
Total Debt Repaid | -120.69 | -321.27 | -457.62 | -66.19 | -122.65 | -766.26 |
Net Debt Issued (Repaid) | 534.61 | -153.23 | -34.18 | 2,435 | -2.94 | -648.37 |
Issuance of Common Stock | 2.13 | - | 999.9 | - | - | - |
Common Dividends Paid | - | -10.03 | -9.72 | -10.44 | -9.21 | -3.63 |
Other Financing Activities | -280.42 | -208.78 | -132.19 | -81.22 | -50.29 | -134.19 |
Financing Cash Flow | 256.33 | -372.04 | 823.81 | 2,343 | -62.44 | -786.18 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 0 | - |
Net Cash Flow | 688.65 | 145.87 | -274.65 | 169.94 | 54.07 | 19.4 |
Free Cash Flow | 419.75 | 470.42 | -1,202 | -2,142 | 187.86 | 748.52 |
Free Cash Flow Growth | - | - | - | - | -74.90% | 932.11% |
Free Cash Flow Margin | 4.81% | 5.74% | -14.89% | -31.01% | 2.41% | 15.35% |
Free Cash Flow Per Share | 4.18 | 4.69 | -12.20 | -22.09 | 1.94 | 7.72 |
Cash Interest Paid | 280.42 | 208.78 | 126.59 | 79.06 | 48.09 | 134.19 |
Cash Income Tax Paid | 207.26 | 228.12 | 270.44 | 276.96 | 330.57 | 94.03 |
Levered Free Cash Flow | -316.48 | -80.69 | -1,421 | -2,332 | -151.59 | 547.1 |
Unlevered Free Cash Flow | -116.21 | 63.24 | -1,329 | -2,290 | -126.55 | 620.64 |
Change in Working Capital | -227.18 | 74.43 | -1,302 | -1,353 | -107.2 | 81.55 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.